Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebokitug (CM-101) in NAFLD/NASH (SPARK)
NCT06044467Phase 1Completed
- Sponsor
- Chemomab Therapeutics
- Start
- Dec 2018
- Primary completion
- Apr 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of nebokitug in non-alcoholic fatty liver disease (NAFLD) and Nonalcoholic steatohepatitis (NASH) (4 arms), sponsored by Chemomab Therapeutics. Primary endpoints: Incidence and characteristics of adverse events at 18 weeks and Anti-drug antibodies at 18 weeks. Started Dec 2018; status: completed.
02
Drugs
nebokitug
03
Conditions
non-alcoholic fatty liver disease (NAFLD)Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT06044467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06044467.